Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials Tirzepatide meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and without PAP therapy, and based on these results Lilly plans to submit these data for global regulatory reviews INDIANAPOLIS ,... Read More

INDIANAPOLIS , April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the general public can access a live webcast of... Read More

INDIANAPOLIS , March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a... Read More

INDIANAPOLIS , March 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of donanemab in early symptomatic Alzheimer's disease. The FDA has informed Lilly it wants... Read More

Two new films draw attention to the importance of treating obesity as a disease and the appropriate use of anti-obesity medications INDIANAPOLIS , March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines... Read More

INDIANAPOLIS , March 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego . The presentations will include new preclinical data for a fully human monoclonal anti-Nectin-4 antibody conjugated to a... Read More

INDIANAPOLIS , Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6 , 2024. Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at... Read More

INDIANAPOLIS , Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson , group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity. "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at Lilly.... Read More

Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small... Read More

INDIANAPOLIS , Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton , executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024 . She will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is actively underway... Read More

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations... Read More

INDIANAPOLIS , Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the... Read More

Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rights Henlius to facilitate clinical development for the initiated Phase 3 MRCT (ELAINE-3) of lasofoxifene in the territory Sermonix receives upfront payment, milestone payments of up to $58M and royalties upon commercialization in the territory COLUMBUS,... Read More

INDIANAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing... Read More

INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11 , 2024. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at... Read More

INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances... Read More

INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled... Read More

INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell malignancies. These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual... Read More

People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved... Read More

INDIANAPOLIS , Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on March 8, 2024 to shareholders of record at the close of business on Feb. 15, 2024. About Lilly Lilly unites caring with discovery to create... Read More

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the intent-to-treat population and 14.9 months for women with visceral disease, however OS outcomes were not statistically significant Additional analyses of Verzenio in metastatic and early breast cancer, as well as imlunestrant... Read More

Express Scripts to add Zepbound to National Preferred Formulary INDIANAPOLIS , Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound ™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m 2 or greater), or those who are overweight (with a BMI of 27 kg/m 2 or greater) and also have weight-related medical problems such as... Read More

INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled... Read More

The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an overall response rate of 72% INDIANAPOLIS , Dec. 1, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S.... Read More

Scheduled to open in the first half of 2024, Lilly's new Gateway Labs location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies INDIANAPOLIS , Nov. 28, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in... Read More

Alexandria and Lilly, which began their strategic relationship in 2008, are collaborating to support and accelerate the development of promising early-stage companies in the growing San Diego life science ecosystem PASADENA, Calif. , Nov. 28, 2023 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life... Read More

Company also commits to investing up to $100 million in German early-stage life sciences ecosystem INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany . This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network... Read More

INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled... Read More

INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28 , 2023. Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:50 p.m., Eastern time . A live audio webcast will be available on the "Webcasts &... Read More

INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled... Read More

Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only... Read More

INDIANAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego . The presentations will provide updated, longer follow-up clinical safety and... Read More

Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue in Q3 2023 increased 24%. Pipeline progress included FDA approvals of Omvoh for the treatment of adults with moderately to severely active ulcerative colitis and an... Read More

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition's unknown nature and the benefits of complete testing Clinical guidelines recommend both blood and urine tests for complete screening for kidney disease: estimated glomerular filtration rate (eGFR) and urine... Read More

INDIANAPOLIS , Nov. 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on Dec. 8, 2023 to shareholders of record at the close of business on Nov. 15, 2023. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the... Read More

Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials Omvoh delivered significant improvement in bowel urgency, reported by people with UC as one of the most disruptive symptoms Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and... Read More

INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8 , 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA ; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor... Read More

- In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) - In the Phase 3 LIBRETTO-531 study, Retevmo provided a 72% improvement in PFS compared to cabozantinib or vandetanib in patients with advanced or metastatic... Read More

INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time . Investors, media and the general public can access a live... Read More

Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% at 5 years These data reinforce two years of Verzenio plus endocrine therapy as the standard of care for these patients in this curative setting Use of Verzenio as a treatment option in this setting is supported by an NCCN®... Read More

First readout of two-year data from long-term extension study INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and... Read More

The full results of the SURMOUNT-3 trial were published in Nature Medicine and simultaneously presented at ObesityWeek ® 2023 INDIANAPOLIS , Oct. 15, 2023 /PRNewswire/ -- Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in Nature Medicine and... Read More

Mirikizumab demonstrated clinical remission and endoscopic response for patients with moderately to severely active Crohn's disease through 52 weeks The study achieved the coprimary endpoints and all major secondary endpoints versus placebo This successful Phase 3 trial will be the basis of global regulatory submissions for Crohn's disease INDIANAPOLIS , Oct. 12, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)... Read More

INDIANAPOLIS , Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio ® (abemaciclib; a CDK4/6 inhibitor), Retevmo ® (selpercatinib; a rearranged during transfection [RET] inhibitor), and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place... Read More

INDIANAPOLIS , Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and... Read More

INDIANAPOLIS , Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team. Mike Mason , executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company. Over the last two decades, Mason has served in the leadership of Lilly's Neuroscience and Diabetes businesses to achieve significant... Read More

INDIANAPOLIS , Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope... Read More

In the letter, the FDA stated no concerns about the clinical data package, safety or label for lebrikizumab INDIANAPOLIS , Oct. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema). The letter cited... Read More

Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance ® (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and cardiovascular death in adults with CKD, as established in the EMPA-KIDNEY phase III trial EMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to demonstrate a statistically significant... Read More

INDIANAPOLIS , Aug. 29 , 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 21st Annual Global Healthcare Conference, Sept. 11-12 , 2023. Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat on Sept. 11 at 2:55 p.m., Eastern time . A live audio webcast will be... Read More

INDIANAPOLIS , Aug. 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET) -mutant medullary thyroid cancer (MTC). The study met its primary endpoint,... Read More

INDIANAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity. "Combining our current incretin portfolio,... Read More

INDIANAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. "Make life better – that's the phrase that guides everything we do at Lilly," said Ruth... Read More

INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150... Read More

Revenue in Q2 2023 increased 28% as a result of volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as $579.0 million from the sale of rights for Baqsimi. Excluding revenue from Baqsimi, and COVID-19 antibodies in 2022, revenue in Q2 2023 increased 22%. Pipeline progress included positive results in the Phase 3 TRAILBLAZER-ALZ 2 study and the submissions of donanemab for traditional approval to the FDA... Read More

INDIANAPOLIS , Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab – as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC). The study met its primary... Read More

Participants in SURMOUNT-3, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% from study entry over 84 weeks Participants in SURMOUNT-4 achieved 21.1% weight loss during a 36-week tirzepatide lead-in period and an additional 6.7% weight loss during a 52-week continued treatment period, for a total mean weight loss of 26.0%... Read More

INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time . Investors, media and the general public can access a live... Read More

INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to... Read More

Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer's disease patients, lowering their risk of disease progression; nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year Additional subpopulation analyses presented live showed that those study participants at earliest stage of disease had even greater benefit,... Read More

Medicxi co-led Company's US$70 million Series A less than 2 years ago Third Medicxi portfolio exit to US biopharma in last 12 months LONDON , GENEVA and JERSEY, British Isles , July 14, 2023 /PRNewswire/ -- Medicxi, a leading European life sciences investment firm, announces that its portfolio company, Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the... Read More

INDIANAPOLIS and NEW YORK , July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to... Read More

INDIANAPOLIS , July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast will begin at 1:30 p.m. Eastern time , and remarks will primarily focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial, as well as the broader landscape in Alzheimer's disease. A live audio webcast will be available on... Read More

INDIANAPOLIS , July 6, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine (NEJM) published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of an investigational use of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with chronic lymphocytic... Read More

INDIANAPOLIS and CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases. Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell... Read More

In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% at 48 weeks Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program INDIANAPOLIS , June 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks,... Read More

INDIANAPOLIS , June 26, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on Sept. 8, 2023 to shareholders of record at the close of business on Aug. 15, 2023. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the... Read More

Detailed results presented at the American Diabetes Association's ® 83 rd Scientific Sessions Lilly has completed tirzepatide's submission for chronic weight management to the FDA INDIANAPOLIS , June 24, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) tirzepatide (10 mg and 15 mg) for chronic weight management in... Read More

In additional phase 2 data, published in The Lancet, orforglipron achieved mean reduction in A1C up to 2.1% at 26 weeks in adults with type 2 diabetes Lilly is investigating orforglipron, its first nonpeptide oral GLP-1 receptor agonist, for chronic weight management in the ATTAIN phase 3 clinical program and for type 2 diabetes in the ACHIEVE phase 3 clinical program INDIANAPOLIS, June 2 3, 2023 /PRNewswire/ -- Eli Lilly... Read More

Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS , June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and... Read More

Full SURMOUNT-2 phase 3 data on the efficacy and safety of tirzepatide for chronic weight management in adults with obesity or overweight and type 2 diabetes New phase 2 data for retatrutide and orforglipron showcase promise of Lilly's pipeline and commitment to transform diabetes and obesity care INDIANAPOLIS , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present 40 abstracts across its diabetes and... Read More

Nationwide effort to inform people living with diabetes about how to access affordable insulin and give back to the diabetes community INDIANAPOLIS , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is teaming up with the American Diabetes Association ® (ADA) and Adam Duvall , American professional baseball player, to launch a nationwide effort to increase awareness of insulin affordability solutions for all... Read More

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif. , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development,... Read More

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality performed numerically better than the active comparator on key secondary endpoints of the CHALLENGE-MIG trial The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with... Read More

New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy across age groups and in patients who had dose adjustments with benefit maintained at four-year follow-up; overall quality of life during the Verzenio treatment period shown to be similar to endocrine therapy alone Updated data from the Phase 1/2 BRUIN trial of Jaypirca in... Read More

INDIANAPOLIS , May 30, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023 . Anat Ashkenazi, Lilly executive vice president and chief financial officer, will participate in a fireside chat on June 12 at 4:20 p.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor... Read More

Reduced greenhouse gas emissions by 20% Improved access to Lilly insulins in the U.S. Nearly doubled patients reached in resource-limited settings through global health efforts INDIANAPOLIS , May 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's ambitious sustainability goals, which are critical to... Read More

Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA) Study evaluated a novel approach to treating patients with autoimmune diseases INDIANAPOLIS , May 18, 2023 /PRNewswire/ -- The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in rheumatoid arthritis (RA), in which peresolimab met the... Read More

INDIANAPOLIS , May 11, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany , and virtually. The company-sponsored abstracts include new analyses of clinical data in approved and investigational uses... Read More

INDIANAPOLIS , May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company's commitment to going beyond the medicines it makes to have a positive impact on patients and society through for-profit investments. The portfolio is aligned with Lilly's efforts to combat racial injustice and its effects... Read More

First interim Phase 2 data of an IL-23p19 antagonist in pediatric patients New analysis from the pivotal Phase 3 LUCENT-1 and LUCENT-2 studies INDIANAPOLIS , May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative colitis (UC) that further support the efficacy and safety seen in previous pivotal studies.... Read More

INDIANAPOLIS , May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023 . Patrik Jonsson , executive vice president, president of Lilly Immunology and Lilly USA , and chief customer officer, will participate in a fireside chat on Wednesday, May 10 at 1 p.m., Eastern time . A live audio webcast will be available on the "Webcasts... Read More

Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB) Phase 3 trial met primary endpoint and all secondary endpoints measuring cognitive and functional decline Donanemab treatment slowed clinical decline by 35% compared to placebo, and resulted in 40% less decline on the ability to perform activities of daily living Over half of... Read More

INDIANAPOLIS , May 2, 2023 /PRNewswire/ -- To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli Lilly and Company (NYSE: LLY) today announced grants totaling $500,000 to four local nonprofits that offer education assistance to Deferred Action for Childhood Arrivals (DACA) recipients, also known as Dreamers. Currently, Indiana is one... Read More

INDIANAPOLIS , May 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on June 9, 2023 to shareholders of record at the close of business on May 15, 2023. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the... Read More

INDIANAPOLIS , May 1, 2023 /PRNewswire/ -- New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further... Read More

Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth from Mounjaro, Trulicity, Verzenio and Jardiance. Pipeline progress included positive results in the tirzepatide Phase 3 SURMOUNT-2 study; FDA approval of an expanded indication for Verzenio; approval of mirikizumab in Japan ; and... Read More

Participants with obesity or overweight and type 2 diabetes taking tirzepatide lost up to 34.4 lb. (15.6 kg) Lilly plans to complete rolling submission to the FDA in the coming weeks INDIANAPOLIS , April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2. The study... Read More

Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly's mission to help more people benefit from BAQSIMI INDIANAPOLIS and RANCHO CUCAMONGA, Calif. , April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI ® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals,... Read More

In addition to $3.7 billion investment in Boone County , Lilly will commit $15 million to Ivy Tech to foster a diverse talent pipeline for high-tech manufacturing jobs INDIANAPOLIS , April 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County ,... Read More

INDIANAPOLIS , April 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab biologic license application (BLA) for the treatment of ulcerative colitis (UC). In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data package, safety, or... Read More

INDIANAPOLIS , April 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the general public can access a live... Read More

INDIANAPOLIS , March 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando , April 14 – 19, 2023. The presentations include the first clinical data from the Phase 1 studies of LY3537982 (KRAS G12C inhibitor) and LY3410738 (IDH inhibitor) and the Phase 2 study of... Read More

Results showed solanezumab did not slow cognitive decline in preclinical Alzheimer's disease or reduce risk of progression to symptomatic Alzheimer's disease Solanezumab targets soluble amyloid beta, and treatment did not result in clearance of brain amyloid plaque Lilly remains committed to fighting Alzheimer's disease, with plaque-clearing mechanisms such as donanemab and remternetug, both in ongoing Phase 3 trials... Read More

The application is based on phase III results from the DINAMO trial showing Jardiance ® (empagliflozin) tablets significantly reduced A1c (a marker of average blood sugar) versus placebo in participants aged 10-17 living with type 2 diabetes If approved, Jardiance would be the first SGLT2 inhibitor indicated for this vulnerable population RIDGEFIELD, Conn. and INDIANAPOLIS , March 8, 2023 /PRNewswire/ -- The U.S. Food and... Read More

The findings, from the COORDINATE-Diabetes trial, demonstrate the benefit of clinic-level educational interventions, including a focus on coordinating care between cardiology and diabetes care providers Results were presented at the Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials Session 2023 and simultaneously published in Journal of the American Medical... Read More

High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade, regardless of Ki-67 score Approval supported by four-year data from the monarchE trial; Verzenio added to adjuvant endocrine therapy (ET) reduced the risk of recurrence by 35% compared to adjuvant ET alone... Read More

INDIANAPOLIS , March 1, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month. Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system... Read More

The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial, which showed Jardiance® (empagliflozin) tablets significantly reduced the risk of kidney disease progression* or cardiovascular death in adults with CKD by 28% (absolute risk reduction [ARR]: 3.8%) compared with placebo, both on top of standard of care. RIDGEFIELD, Conn. and INDIANAPOLIS , Jan. 20, 2023 /PRNewswire/ --... Read More

Accelerated approval application was based on Phase 2 trial showing amyloid plaque lowering Complete response letter based on limited number of patients with 12-month drug exposure data in the accelerated approval submission; no other deficiencies were identified Definitive Phase 3 readout and submission for traditional approval remain on track for mid-year 2023 INDIANAPOLIS , Jan. 19, 2023 /PRNewswire/ -- Eli Lilly and... Read More